Results 41 to 50 of about 1,193,298 (158)

Comparison of the efficacy of second and third generation lentiviral vector transduced CAR CD19 T cells for use in the treatment of acute lymphoblastic leukemia both in vitro and in vivo models.

PLoS ONE, 2023
T cells genetically engineered to express a chimeric antigen receptor (CAR) specifically binding to a CD19 antigen has become the frontline of hematological malignancies immunotherapy.
Piamsiri Sawaisorn, Korakot Atjanasuppat, Kitipong Uaesoontrachoon, Parin Rattananon, Worapapar Treesuppharat, Suradej Hongeng, Usanarat Anurathapan   +6 more
doaj   +2 more sources

Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma

Frontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies.
Yifan Pang, Nilanjan Ghosh
doaj   +1 more source

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines

Journal of Immunotherapy for Cancer, 2017
BackgroundClinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse.
D. Schneider, Y. Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, A. Kaiser, B. Dropulić, R. Orentas   +8 more
semanticscholar   +1 more source

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial

Nature Communications
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target ...
Ming Shi, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, W. Sang, K. Qi, Depeng Li, F. Zhu, Zhenyu Li, J. Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Junnian Zheng, Jiang Cao   +21 more
semanticscholar   +1 more source

Toxicities of CD19 CAR‐T cell immunotherapy

American journal of hematology/oncology, 2019
CD19‐targeted chimeric antigen receptor (CAR)‐modified T (CAR‐T) cell immunotherapy has demonstrated impressive results in B‐cell malignancies, and CAR‐T cell therapies targeting other antigens are in development for other cancers.
A. Hirayama, C. Turtle
semanticscholar   +1 more source

Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies

International Journal of Molecular Sciences, 2020
Oncology immunotherapy has been a significant advancement in cancer treatment and involves harnessing and redirecting a patient’s immune response towards their own tumour.
R. Abbott, R. Cross, Misty R. Jenkins
semanticscholar   +1 more source

A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay

Frontiers in Pharmacology, 2023
Introduction: Cellular immunotherapy has greatly improved cancer treatment in recent years. For instance, chimeric antigen receptor (CAR) T cell therapy has been proven highly effective in treating hematological malignancies, and many CAR cell designs ...
YangHao Fu, TianDuo Wang, John A. Ronald, John A. Ronald   +3 more
doaj   +1 more source

Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system

Journal for ImmunoTherapy of Cancer
Background A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy.Methods We developed a second-generation CAR ...
Supannikar Tawinwung, Nattiya Hirankarn, Asmita Khaniya, S M Ali Hossieni Rad, Josh Halpin, Alexander McLellan, Koramit Suppipat   +6 more
doaj   +1 more source

CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury

Annals of the Rheumatic Diseases
Objectives Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are life-threatening systemic autoimmune diseases manifesting in the kidneys as necrotizing crescentic glomerulonephritis (NCGN).
D. Lodka, Maria Zschummel, M. Bunse, A. Rousselle, Janis Sonnemann, R. Kettritz, Uta E Höpken, A. Schreiber   +7 more
semanticscholar   +1 more source

Increased NFAT activity with dual CAR stimulation in CD19xCD22 CAR T-cells is associated with decreased exhaustion and improved survival

Journal for ImmunoTherapy of Cancer
Background Chimeric antigen receptor (CAR) T-cell therapy is effective in treating B-cell malignancies, however relapse due to lack of CAR persistence and antigen-modulated escape remains common. Multiple strategies to simultaneously target CD19 and CD22
Terry J Fry, Amanda J Novak, Alexander W Rankin, Catherine Pham-Danis, Etienne Danis, M Eric Kohler   +5 more
doaj   +1 more source